Acumen Pharmaceuticals ABOS
NASDAQ ABOS
$2.86 +0.01 (+0.35%)
At close: Sep 10, 2026 · 4:00 PM EDT

Acumen Pharmaceuticals (ABOS) Notes Payables (2025 - 2026)

Acumen Pharmaceuticals' (ABOS) quarterly Notes Payables came in at $19.7 million in Q2 2026, up 39.3% quarter-over-quarter from $14.1 million in Q1 2026.

Analysis

Acumen Pharmaceuticals (ABOS) Notes Payables (2025 - 2026) Analysis & Trends

Acumen Pharmaceuticals has disclosed Notes Payables across 2 years of filings, most recently posting $19.7 million for Q2 2026.

  • In Q2 2026, Notes Payables changed N/A year-over-year to $19.7 million; the TTM figure through Jun 2026 stood at $19.7 million (changed N/A YoY), while the FY2025 annual figure was $8.8 million, changed N/A from the prior year.
  • Notes Payables came in at $19.7 million for Q2 2026 at Acumen Pharmaceuticals, up from $14.1 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $19.7 million in Q2 2026 to a low of $3.6 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Acumen Pharmaceuticals 205.91 Mn 205.91 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 19.67 Mn
Mar 31, 2026 14.12 Mn
Dec 31, 2025 8.77 Mn
Sep 30, 2025 3.60 Mn